Abstract
The COVID-19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment who represent a vulnerable population for SARS-CoV-2 infection. Aggressive lymphoid neoplasms, such as diffuse large B cell lymphoma and high-grade B cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed to minimise the risk of SARS-CoV-2 infection while continuing haematological treatment. In this report, we analyse the management of front-line therapy in 18 patients during the COVID-19 outbreak, as well as the results of the implemented measures in their outcome.
Keywords: B cell lymphoma; COVID-19; SARS-CoV-2; haematological malignancies; high-grade.
【저자키워드】 COVID-19, SARS-CoV-2, haematological malignancies, B cell lymphoma, high-grade., 【초록키워드】 Treatment, therapy, SARS-COV-2 infection, COVID-19 pandemic, risk, haematological malignancies, outcome, B cell, COVID-19 outbreak, lymphoma, management, Patient, Cancer patients, disease, Care, Clinical practice, High-grade, Neoplasms, best, vulnerable population, active treatment, measure, lymphoid, treated, changed, Aggressive, 【제목키워드】 Treatment, B cell, managing,